Florian Wegwitz

Goettingen, NI, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

PTHrP-associated hypercalcemia in gynecologic malignancies: a scoping review.

PTHrP-associated hypercalcemia in gynecologic malignancies: a scoping review.

Journal: Archives of gynecology and obstetrics

Published: March 25, 2026

Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.

Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.

Journal: Cancer research communications

Published: October 27, 2025

Identification of tumor-promoting functions of the Homeobox family transcription factor MSX1 in cervical cancer.

Identification of tumor-promoting functions of the Homeobox family transcription factor MSX1 in cervical cancer.

Journal: Cell death discovery

Published: July 25, 2025

MUC1 as a Survival Effector of Radiotherapy-Induced Epithelial Hybrid States in Basal-Like Breast Cancer.

MUC1 as a Survival Effector of Radiotherapy-Induced Epithelial Hybrid States in Basal-Like Breast Cancer.

Journal: International journal of cancer

Published: April 01, 2025

RNF20/RNF40 supports the aggressive behavior in cervical cancer by regulating a peroxisome-based anti-ferroptotic mechanism.

RNF20/RNF40 supports the aggressive behavior in cervical cancer by regulating a peroxisome-based anti-ferroptotic mechanism.

Journal: Cell communication and signaling : CCS

Published: September 28, 2024

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Journal: Cell death and differentiation

Published: September 04, 2024

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Journal: bioRxiv : the preprint server for biology

Published: March 11, 2024

Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer.

Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer.

Journal: Nature communications

Published: December 14, 2023

A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction.

A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 13, 2023

USP22 supports the aggressive behavior of basal-like breast cancer by stimulating cellular respiration.

USP22 supports the aggressive behavior of basal-like breast cancer by stimulating cellular respiration.

Journal: Cell communication and signaling : CCS

Published: June 28, 2023

RNF40 epigenetically modulates glycolysis to support the aggressiveness of basal-like breast cancer.

RNF40 epigenetically modulates glycolysis to support the aggressiveness of basal-like breast cancer.

Journal: Cell death & disease

Published: December 05, 2022

Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma.

Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma.

Journal: Molecular cancer research : MCR

Published: November 14, 2022

Showing 1-12 of 48

Last Updated: 09/26/2026